Weight loss injections, primarily glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide (Wegovy) and tirzepatide (Zepbound), work through multiple mechanisms to promote weight reduction
It is not for human or veterinary use, and must not be used in food, drugs, diagnostics, therapeutics, or cosmetics
Phase 2 clinical trials showed weight loss of up to -24.2% over 48 weeks
Research has shown that BPC-157 plays a role in accelerating the healing of a wide range of tissues, including muscles, tendons, ligaments, and even the gut lining
Many people don't realize how depleted they felt until they supplement
Hormonal control of muscle growth